Aeterna Zentaris Reports Updated Phase 1 Trial Results for AEZS-108 in ... - MarketWatch (press release)

Aeterna Zentaris Reports Updated Phase 1 Trial Results for AEZS-108 in ... MarketWatch (press release) Aeterna Zentaris is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, multiple myeloma, endometrial, ovarian, prostate and bladder cancer. and more »

Relationship between aberrant methylation of FAS promoter and biological ... - UroToday

Relationship between aberrant methylation of FAS promoter and biological ... UroToday Promoter methylation of Fas gene was detected by methylation-specific PCR (MSP) in 4 bladder cancer cell lines, 50 human bladder urothelial carcinoma samples and l0 normal bladder tissue samples. Correlation of the aberrant methylation of Fas promoter ...

Outpatient diagnostic of bladder tumours in flexible cystoscopes: Evaluation ... - UroToday

Outpatient diagnostic of bladder tumours in flexible cystoscopes: Evaluation ... UroToday The bladder was first examined in standard white light followed by PDD. PDD was superior to white light diagnosis; PDD was positive in 16 patients (22%) where white light showed a normal bladder mucosa. Four of these patients had bladder tumour [4/73, ...

Risk stratification of organ confined bladder cancer after radical cystectomy ... - UroToday

Risk stratification of organ confined bladder cancer after radical cystectomy ... UroToday We tested whether assessing the expression of cell cycle related proteins (p53, pRB, p21 and p27) could predict clinical outcomes after radical cystectomy in patients with organ confined urothelial carcinoma of the bladder.

Molecular Insight Pharmaceuticals, Inc. Presents Human Data Demonstrating ... - MarketWatch (press release)

Molecular Insight Pharmaceuticals, Inc. Presents Human Data Demonstrating ... MarketWatch (press release) CAMBRIDGE, MA, Feb 02, 2012 (MARKETWIRE via COMTEX) -- Molecular Insight Pharmaceuticals, Inc. (MIP) will present first human data on the molecular imaging of metastatic prostate cancer in bone and soft tissue with their new 99mTc-radiolabeled ... SOURCE: Molecular Insight Pharmaceuticals, Inc.Marketwire (press release) all 3 news articles »